Eris Biotech

We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. In addition, our drugs have a unique delivery mechanism known as hypoxia-activated prodrugs (HAPs). HAPs are drugs designed to become active in a hypoxic (low oxygen) environment, which is a hallmark of the majority of solid tumors. By delivering active drugs only to the tumor site, we hope to overcome systemic toxicity in cancer therapeutics. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.